PC
PCRX icon

Polar Capital’s Pacira BioSciences PCRX Stock Holding History

Polar Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-600,425
Closed -$25.8M – 286
2018
Q4 		$25.8M Buy
600,425
+318,601
+113% +$14.9M 0.28% 116
2018
Q3 		$13.9M Buy
+281,824
New +$12.2M 0.12% 168
2017
Q1 		– Sell
-25,000
Closed -$808K – 264
2016
Q4 		$808K Sell
25,000
-9,100
-27% -$304K 0.01% 246
2016
Q3 		$1.17M Sell
34,100
-14,096
-29% -$552K 0.02% 233
2016
Q2 		$1.63M Buy
48,196
+22,162
+85% +$1.09M 0.03% 232
2016
Q1 		$1.38M Buy
26,034
+5,045
+24% +$295K 0.03% 228
2015
Q4 		$1.61M Buy
20,989
+6,099
+41% +$345K 0.03% 224
2015
Q3 		$612K Sell
14,890
-20,030
-57% -$1.23M 0.01% 255
2015
Q2 		$2.47M Buy
34,920
+27,767
+388% +$2.19M 0.05% 217
2015
Q1 		$636K Buy
7,153
+2,066
+41% +$210K 0.01% 264
2014
Q4 		$451K Buy
+5,087
New +$481K 0.01% 261
2014
Q2 		– Sell
-197,091
Closed -$13.8M – 279
2014
Q1 		$13.8M Sell
197,091
-109,453
-36% -$7.44M 0.32% 116
2013
Q4 		$17.6M Sell
306,544
-53,875
-15% -$2.83M 0.42% 82
2013
Q3 		$17.3K Sell
360,419
-18,299
-5% -$667K 0.46% 67
2013
Q2 		$11M Buy
+378,718
New +$11M 0.38% 109

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Polar Capital's PCRX Position: Q1 2019 in Review

Polar Capital sold out of Pacira BioSciences (PCRX) in Q1 2019, closing a stake of 600,425 shares — an estimated $25.8M sold.

Polar Capital first reported a position in PCRX in Q2 2013 and held it in 15 quarters. The position peaked at $25.8M in Q4 2018. 210 funds tracked by Wall St. Rank hold PCRX as of Q1 2019.

  • Polar Capital reported no remaining Pacira BioSciences position as of Q1 2019 after selling out during the quarter.
  • Polar Capital sold 600,425 Pacira BioSciences shares in Q1 2019, an estimated $25.8M.
  • Polar Capital first reported a position in Pacira BioSciences in Q2 2013 and held it in 15 quarters.
  • Polar Capital's Pacira BioSciences position peaked at $25.8M in Q4 2018.
  • 210 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2019.

Based on Polar Capital's 13F filing for Q1 2019, filed 15 May 2019.